Analyst rates Anthropic a Hold: a high-single-digit price-to-sales multiple implies fair value above $100, while AI ...
Analyst rates GDXY a cautious Hold: call spreads cushioned losses by only 4–5 points, while miner free cash flow could fall 2 ...
Analyst rates RISR a Buy: positive carry and negative duration could hedge tech and bonds, while lower inflation could make ...
Gencor Industries remains rated a ‘strong buy’ due to its compelling risk-reward profile and recent operational rebound. GENC ...
Analyst rates Oracle a high-risk Buy near $104, with a $188 12-month target tied to earnings delivery and multiple expansions ...
The bear case on Anthropic: its 46x estimated FY2029 adjusted P/E could compress toward 20x–25x as lockup shares become ...
Structural forces are driving demand for robotics. Aging populations, operational challenges, and workplace safety needs ...
Seapeak's Series B preferred shares are an attractive option for investors. The high-yielding preferreds stand out among ...
Limited capacity outside China and long mine lead times have supported a price premium for ex-China supply, which could ...
Upgrading CG Oncology to Hold from Sell: Phase 3 success de-risks cretostimogene, but the valuation still demands exceptional ...
The bull case for Paychex: a $134.61 target implies 19.52% upside over 12–18 months at 21x fiscal 2028 EPS, before dividends.
Analyst rates Amerant Bancorp a cautious Buy: loan growth resumes, Q3 margin reaches 3.77%, and shares trade below 10x ...